Annual Report 2003 Aventis - Sanofi

Africa, we supplied 60 000 vials of efl ornithine,
100 000 vials of melarsoprol and 100 000 vials of
pentamidine. Through the Aventis Foundation, we
are working with the Nelson Mandela Foundation
to combat tuberculosis in South Africa. Our human
vaccines business continues to play a pivotal role in
the Global Polio Eradication Initiative and has reinforced
its commitment to strengthening vaccination
systems in developing countries through EPIVAC.
Pharma scenarios and the business case for
sustainable healthcare
The pharmaceutical industry is facing a set of issues
that have the potential to signifi cantly alter
the current business model. It is thus essential
to anticipate key future developments through a
strong, fl exible and durable policy framework. With
this aim in mind, in 2003 we advanced the “Pharma
Scenarios for Sustainable Healthcare” project. By describing
the landscape in which future challenges,
dilemmas and opportunities could play themselves
out, the project aims to facilitate new ways of looking
at established paradigms and develop strategies
to position the company for a sustainable future.
Addressing sustainability issues
With a view to both effectively managing and
shaping business-critical topics, we actively participate
in industry and political dialogues. In 2003,
company experts continued to work closely with
patient groups, legislators and non-governmental
organizations on issues such as timely and equitable
access to products and information for patients,
restoring the competitiveness of the research-based
pharmaceutical industry in Europe and intellectual
property protection.
To track and report annual progress on our environment,
health and safety Journey to EHS Excellence,
an annual scorecard was introduced in 2003.
>> 47